pre- and post-allohsct treatment in mds
Published 2 years ago • 65 plays • Length 5:43Download video MP4
Download video MP3
Similar videos
-
2:35
methods of optimizing transplantation in mds
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
6:20
maintenance therapy after allogeneic hsct in mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
2:15
optimizing transplantation for mds
-
5:16
blood and marrow transplant in mds
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
2:11
the management of post-mpn aml
-
2:04
state-of-the-art treatment for hr-mds
-
2:36
phase ii study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:37
allo-sct in older patients with mds: selection, donors, and timing
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
0:59
bmt ctn 1102: pre-transplantation qol measures improve prognostication in hr-mds
-
2:16
the potential use of proteomics for predicting relapse in patients with mds undergoing allosct
-
1:29
mutational profiles of mds patients undergoing allo-hsct
-
1:43
reasons why there are fewer treatment options for mds patients and hope for the future
-
1:18
update on immunotherapy in mds